🟢 BioXcel Therapeutics is trading 5.46% up in after-hours trading after positive late-stage at-home agitation-treatment data

BioXcel Therapeutics is trading 5.46% up at $0.85 in after-hours trading after positive late-stage data for its at-home agitation treatment strengthened confidence in the pipeline.

• The SERENITY At-Home program supports potential expansion of IGALMI use.
• The August 21, 2026 lender deadline for financing or repayment remains a major risk.
• The move follows a regular-session close of $0.80 and appears primarily company-driven despite mixed broader-market performance; the financing overhang may be limiting the gain.